APA (7th ed.) Citation

Breillat, P., Mathian, A., Rozenberg, F., Dutheil, A., Barbaud, A., Amoura, Z., & Chasset, F. (2023). Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus, 32(3), 453. https://doi.org/10.1177/09612033231153536

Chicago Style (17th ed.) Citation

Breillat, Paul, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, and François Chasset. "Is There an Increased Risk of Severe COVID-19 Among Patients with Systemic Lupus Erythematosus Treated with Anifrolumab?" Lupus 32, no. 3 (2023): 453. https://doi.org/10.1177/09612033231153536.

MLA (9th ed.) Citation

Breillat, Paul, et al. "Is There an Increased Risk of Severe COVID-19 Among Patients with Systemic Lupus Erythematosus Treated with Anifrolumab?" Lupus, vol. 32, no. 3, 2023, p. 453, https://doi.org/10.1177/09612033231153536.